

MEDICAL REVIEW GUIDELINE

Apretude Diagnosis Specific Policy



Apretude[®] (cabotegravir)

Effective Date: 5/1/2024

Medical Care Management Committee Approval: 2/15/2024

Contents

Coverage Policy	1
Diagnosis-Specific Criteria	1
Applicable Codes	2
Policy Revision History.....	2

Coverage Policy

This Medical Review Guideline (Guideline) is provided for informational purposes only and does not constitute medical advice. It is intended solely for the use of Community Health Choice, Inc. (Community) clinical staff as a guideline for use in determining medical necessity of requested procedures, medications and therapy. This Guideline does not address eligibility or benefit coverage. Other Policies and Coverage Determination Guidelines may apply. All reviewers must first identify enrollee eligibility, any federal or state regulatory requirements and the plan benefit coverage prior to use of this Medical Review Guideline. If there is a discrepancy between this Guideline and a member's benefit plan, summary plan description or contract, the benefit plan, summary plan description or contract will govern. Community reserves the right, in its sole discretion, to modify its Policies and Guidelines as necessary.

This policy applies to the following Apretude[®] (cabotegravir) product:

HCPCS Code	Description	Maximum Dosage per Administration
J0739	Injection, cabotegravir 1 mg	600 mg IM

Diagnosis-Specific Criteria

Apretude[®] (cabotegravir) will be considered medically necessary for members meeting ALL of the following criteria:

1. Member weight is ≥ 35 kg; AND
2. Used for HIV-1 pre-exposure prophylaxis (PrEP); AND
3. Provider attests that member has a negative HIV-1 test result ≤ 1 week prior to the dose of Apretude; AND
4. Provider confirms that the member will be tested for HIV-1 infection with each subsequent injection; AND
5. Member is not an appropriate candidate for oral PrEP (e.g., difficulty with adherence to prior oral PrEP, significant renal disease); AND
6. Provider attests that member demonstrates treatment readiness by both of the following:
 - a. Member understands the risks of missed doses of Apretude.
 - b. Member has the ability to adhere to the required every 2 months injection and testing

MEDICAL REVIEW GUIDELINE

Apretude Diagnosis Specific Policy



appointments; AND

7. Dosing is in accordance with the United States Food and Drug Administration approved labeling; AND
8. Initial authorization is for no more than 12 months

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive.

HCPCS Code	Description
J0739	Injection, cabotegravir 1 mg

Diagnosis Code	Description
Z29.81	HIV pre-exposure prophylaxis

Policy Revision History

Status	Effective Date	Description
Baseline	TBD	Initial version of Apretude (cabotegravir) Diagnosis Specific Policy